Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous studies have shown that 30% of patients di.
- 02/18/2025
|
Allurion Relaunches in France
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. “We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “Historically, France has been.
- 02/13/2025
|
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%
- The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 02/10/2025
|
Allurion Technologies Shares Are Up Today: What's Going On?
- Allurion Technologies ALUR shares are moving higher Friday, potentially in response to the company's Thursday announcement of a planned clinical study to evaluate the combination of its Allurion Program with GLP-1 agonists.
- 01/24/2025
|
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
- Shares of Allurion Technologies (ALUR) tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market.
- 01/24/2025
|
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company's common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules. In addition, in a concurrent private placement, the Compan.
- 01/24/2025
|
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous.
- 01/23/2025
|
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion's proprietary Balloon technology and the introduction of in.
- 01/21/2025
|
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company's common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Compa.
- 01/14/2025
|
Allurion Technologies, Inc. Announces Reverse Stock Split
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis.
- 12/24/2024
|
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the “Minimum Market Capitalization Standard”.
- 12/02/2024
|
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company's AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the.
- 11/25/2024
|
Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript
- Allurion Technologies Inc. (NYSE:ALUR ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executive Officer Brian Conyer – Vice President-Digital Health Adrian Wild – Senior Vice President-International Commercial Chris Geberth – Chief Financial Officer Conference Call Participants Josh Jennings – TD Cowen Matt Taylor – Jefferies Operator Thank you for standing by. My name is John, and I'll be your conference operator today.
- 11/13/2024
|
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (int.
- 10/30/2024
|
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
- Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.
- 10/24/2024
|
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
- Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.
- 10/09/2024
|
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
- Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.
- 10/04/2024
|
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduc.
- 10/01/2024
|
Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript
- Allurion Technologies Inc. (NYSE:ALUR ) Q2 2024 Earnings Call Transcript August 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Shantanu Gaur - Founder and CEO Chris Geberth - CFO Conference Call Participants Keay Nakae - Chardan Matt Taylor - Jefferies Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.
- 08/13/2024
|
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.
- 07/16/2024
|
Allurion Announces Launch of Offering of Common Stock and Warrants
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.
- 06/26/2024
|
Why Is Allurion (ALUR) Stock Up 140% Today?
- Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name.
- 06/20/2024
|
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite. In the st.
- 06/20/2024
|
Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy
- Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.
- 06/14/2024
|
Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 06/11/2024
|
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024. Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison,.
- 06/11/2024
|
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working.
- 06/05/2024
|
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1.
- 05/30/2024
|
Allurion to Participate in Two Upcoming Investor Conferences in June 2024
- NATICK, Mass.--(BUSINESS WIRE)--Allurion to Participate in Two Upcoming Investor Conferences in June 2024.
- 05/29/2024
|
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change program. This study was cond.
- 05/15/2024
|
Allurion Reports First Quarter 2024 Financial Results and Provides Business Update
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports First Quarter 2024 Financial Results and Provides Business Update.
- 05/14/2024
|
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three oral scientific presentations at the 12th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders – European Chapter (IFSO-EC) held in Vienna, Austria on 2-4 May 2024. Presentations include data from a survey of 133 patients across seven international obesity centers that shows patients on the Allurion Program lost just over 1.
- 05/02/2024
|
Allurion Announces Preliminary First Quarter 2024 Results
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024. Management expects preliminary unaudited results for the period as follows: Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023 Procedural volume growth, as estimated by new app users, reflecting 22% growth ove.
- 04/30/2024
|
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments.
- 04/17/2024
|
Why Is Allurion (ALUR) Stock Up 65% Today?
- Little-known medical device firm Allurion (NYSE: ALUR ) — which is focused on ending obesity via its swallowable and “procedure-less” intragastric balloon — saw its shares skyrocket on Thursday. Earlier this morning, management announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the U.S. ALUR stock likely benefited from rising interest in anti-obesity treatments.
- 04/04/2024
|
Allurion Expands Virtual Care Suite to the United States
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States. Already in use by thousands of providers in over 50 countries, the VCS is a dynamic weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration all under the one digital umbrella, designed.
- 04/04/2024
|
Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript
- Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript
- 03/21/2024
|
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance.
- 03/21/2024
|
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and gu.
- 03/12/2024
|
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years' experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and Chief Legal Officer at Acushnet Company, the parent company of Titleist and other golf.
- 01/29/2024
|
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for ap.
- 01/23/2024
|
World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for ap.
- 01/23/2024
|
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss clinic chain. After recently expanding its commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for.
- 01/17/2024
|
Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide. In the study, 115 patients were randomized to either the Allurion Program with.
- 01/11/2024
|
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake. The global market for anti-obesity medications – specifically of GLP-1s (glucagon-like peptide-1 receptor agonists) – is expected to reach $100 billion by 2030.1 Research has shown these products have significantly alte.
- 01/05/2024
|
Allurion's Digital Platform Gains Traction with Expanded Strategic Partnership
- NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead commercialization of Allurion's rapidly growing digital assets. After a successful 2023 in which it managed over 2,000 patients on Allurion's Virtual Care Suite (VCS) digital platform, Weight Doctors has sig.
- 01/02/2024
|
Allurion Technologies Inc. (ALUR) Q3 2023 Earnings Call Transcript
- Allurion Technologies Inc. (NYSE:ALUR ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Mike Cavanaugh - ICR of Westwicke Shantanu Gaur - Founder and Chief Executive Officer Chris Geberth - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Ross Osborn - Cantor Fitzgerald Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Operator Hello, and welcome to the Allurion Third Quarter Earnings Call. All lines have been placed on mute to prevent any background noise.
- 11/17/2023
|
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023
- NATICK, Mass.--(BUSINESS WIRE)--Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023.
- 11/06/2023
|
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
- NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. “I believe the brisk enrollment in the AUDACITY trial reflects the.
- 10/11/2023
|
